Evidence map›Paper›PMID 39195296›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Phase-Based and Lifetime Health System Costs of Care for Patients Diagnosed with Leukemia and Lymphoma: A Population-Based Descriptive Study.

Anubhav Agarwal, Natasha Kekre, Harold Atkins, Haris Imsirovic, Brian Hutton, Doug Coyle, Kednapa Thavorn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anubhav AgarwalSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada 2 Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada 3 Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada 4 Royal Ottawa Mental Health Center, Ottawa, ON K1Z 7K4, Canada.
Natasha KekreSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada 2 Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada 3 Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada 4 Royal Ottawa Mental Health Center, Ottawa, ON K1Z 7K4, Canada.
Harold AtkinsOttawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0002-6168-3939
Haris ImsirovicOttawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
Brian HuttonSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada 2 Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada 3 Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada 4 Royal Ottawa Mental Health Center, Ottawa, ON K1Z 7K4, Canada.
Doug CoyleSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada 2 Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada 3 Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada 4 Royal Ottawa Mental Health Center, Ottawa, ON K1Z 7K4, Canada.
Kednapa ThavornSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada 2 Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada 3 Department of Medicine, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada 4 Royal Ottawa Mental Health Center, Ottawa, ON K1Z 7K4, Canada.ORCID 0000-0003-4738-8447

Funding

BioCanRx CSEI8Ontario Institute for Cancer Research P.HSR.202
6 · The paper itself

Abstract

Hematologic cancers, notably leukemias and lymphomas, pose significant challenges to healthcare systems globally, due to rising incidence rates and increasing costs. This study aimed to estimate the phase and lifetime health system total costs (not net costs) of care for patients diagnosed with leukemia and lymphoma in Ontario, Canada. We conducted a population-based study of patients diagnosed between 2005 and 2019, using data from the Ontario Cancer Registry linked with health administrative databases. Costs were estimated using a phase-based approach and stratified by care phase and cancer subtype. Acute lymphocytic leukemia (ALL) patients had the highest mean monthly initial (CAD 19,519) and terminal (CAD 41,901) costs among all cancer subtypes, while acute myeloid leukemia (AML) patients had the highest mean monthly cost (CAD 7185) during the continuing phase. Overall lifetime costs were highest for ALL patients (CAD 778,795), followed by AML patients (CAD 478,516). Comparatively, patients diagnosed with Hodgkin lymphoma (CAD 268,184) and non-Hodgkin lymphoma (CAD 321,834) had lower lifetime costs. Major cost drivers included inpatient care, emergency department visits, same-day surgeries, ambulatory services, and specialized cancer drugs. Since 2005, the cost structure has evolved with rising proportions of interventional drug costs. Additionally, costs were higher among males and younger age groups. Understanding these costs can help guide initiatives to control healthcare spending and improve cancer care quality.

Indexed as

Health Care CostsLymphomaAdolescentAdultAgedAged, 80 and overFemaleHumansLeukemiaMaleMiddle AgedOntarioYoung Adulthealth system costsjoinpoint modellingleukemialifetime costslymphomaOntariophase-based costing

Identifiers

PMID39195296
PMCPMC11352321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.